Q3 2019 Earnings Call

Good day and welcome to <unk> in incorporated third quarter Earnings Conference call Today's conference is being recorded.

My pleasure during today's call Mr. Mark Sherman. Please go ahead Sir.

Thank you operator, good morning, everyone and thanks for joining us on Mark Sherman, VP, Treasurer, and Investor Relations I'd like to welcome you to enhance third quarter 2019 earnings conference call I present or is this morning, as interim President and Chief Executive Officer warm development also turning the call, it's Tom the bio SVP and chief.

Financial officer, if anyone needs a copy of the press release or the supplemental presentation. Please contact abernathy Mcgregor at June 123715999, and they'll be happy to send you a copy.

Before we begin I'll ask that you take note of the cautionary language regarding forward looking statements contained in todays press release supplemental presentation and the risk factor section. That's companies 10-K for the year ended December 31st 2018.

Same language applies to comments made on today's conference call, including the QNX session of the live webcast are presented presentation. Today will contain forward looking statements regarding sales margins foreign exchange rate cash flow tax rate acquisition synergies future operating results performance or a worldwide.

Our kids and other topics. These statements should be used with caution are subject to various risks and uncertainties many of which are outside the company's control.

The presentation also includes certain non-GAAP measures as defined by FCC rules, a reconciliation of such non-GAAP measures is contained in the tables in the final section of the press release in the supplemental presentation.

Born and Tom will now provide commentary on the business and discuss results and we'll open the line for questions. After our prepared remarks with that said worn I'll turn the call over to you.

Thanks Mark.

Yes. This is Tom and in my first and ends earnings call. We revisit some of the previous earnings calls to gain a better understanding of the information that our shareholders and analysts would like us to present.

Based on that review, we have revised the company's earnings presentation to present additional information regarding the group's financial performance and outlook.

Adjusted results and the financial analysis of working capital and capital expenditures I Hope you find our presentation more informative, let's start with an overview of the third quarter. Our sales for Q3 were 213.9 million up 4% from the prior year and were driven primarily by organic sales from our life Sciences grew.

Where sales were up 15.6 million or 20% from one year ago.

The third quarter operating income and <unk>, both improved over Q3 2018, GAAP operating income margin expanded 70 basis points from 2.9% last year to 3.6%. This year EPS also improved from a loss of 48 cents per share one year ago to a loss of.

14 cents per share in Q3 2019.

Adjusted operating income margin in 2019 was up slightly to 12.9% from 12.8% in 2018 and our adjusted EPS was 27 cents. This year versus 30 cents. In 2018. Please note that adjusted net income was 11.4 million this quarter and eat.

7 million in Q3 of 2018, and the number of weighted shares outstanding increased 46% to 42 million shares, resulting in EPS number lower than the previous year.

Both reported EBITDA and adjusted EBITDA increased consistently between the periods with adjusted EBITDA, increasing to 40.2 million in Q3, 2019 or 18.8% of sales in comparison to 18.2% of sales the previous year.

And then generated 17.5 million in free cash flow in the third quarter, an increase of 29.4 million over the same quarter, one year ago, resulting in a reduction of not that during the quarter to 855 million.

Some significant highlights during the quarter include our announced plan to improved free cash flow through reductions in operating expenses and reduced capital expenditures.

We also have eliminated the quarterly cash dividend life Sciences operating margins continue to improve power solutions sales were up 2.9% organic growth associated with smart meters and mobile solutions continues to effectively reduced its fixed costs in response to lower sales volumes. We will review these highly.

It's in more detail throughout the presentation.

The company had previously announced a refinancing of its capital structure that we expected to close this week due to the cost profile of the initial refinancing structure. We are evaluating other financing options to ensure we are achieving a result that isn't the best interest of all of our stakeholders, we remain committed to establish.

Capital structure that aligns with our strategic plan and we're optimistic that such a structure can be established on reasonable terms. We have retained external advisors to assist us in fully evaluating our strategic options.

As a result of the delay in the financing our revolving credit facility will be current prior to the filing of our Form 10-Q .

Consequently, the company in response to the technical accounting guidance surrounding these situations and with consultation with our independent auditors will be incorporating going concern language in our 10-Q, we're optimistic that we will be able to establish a capital structure consistent with our strategic plan prior to it.

The expiration of our revolving credit facility in October 2020.

[noise], we've provided additional detail on the select cost reduction initiatives on page five.

When I first started as interim CEO I'm formed our employees that are focus would be on three things one servicing the customer bright by exceeding their expectations for quality and delivery to improving our operating margins and three improving free cash flow with a focus on paying down debt I told the team that our overhead.

I didn't SDMA costs were excessive and we would immediately focus on reducing those expenses to date, we've reduced the headcount of our corporate group by 20%, yielding an immediate 5 million dollar reduction in expense at the same time, we're consolidating the footprint of our corporate group and expect to achieve a reduction in rent of over one point.

5 million annually, we will likely incur a financial pended penalty to exit a portion of the office space early but I believe the payback will be less than one year and our long range plan does not contemplate us needing this space in the future.

Our operating groups are also focus on streamlining overhead related costs power solutions recently announced the closure of the Fairfield facility by the end of this year saving $800000 annually. The bulk of this business will be transferred to other facilities mobile solutions announced the reorganization of its Ohio facilities and.

Late October yielding an additional 1.5 million dollar reduction in fixed fixed expenses.

Life Sciences will continue to focus on margin enhancement, which includes maintaining its current SDMA expense structure, while the group experiences additional growth during 2020.

We will continue to analyze our overall cost structure and facility footprint for additional opportunities for consolidation and improving our cost structure to be more cost competitive.

As we have previously indicated we have also eliminated quarterly cash dividend and our focus on reducing our annual capital expenditures.

Turning to slide six which details our revenues by segment on a consolidated basis total revenue increased 4% for the third quarter versus the prior year life Sciences grew 20% and power solutions grew almost 3% assisted by incremental sales associated with the technical large acquisition that closed in August of low.

Last year.

Mobile solutions posted at reduction in sales due to global automotive headwinds coupled with the GM strike Foreign exchange continue to do we reduced sales as the euro in Brazilian hail weakened versus the U.S. dollar.

On a year to date basis overall sales grew 13.6% driven primarily by the acquisition of Paragon in May of 2018 organic growth within life Sciences and to a lesser expat the sales growth in power solutions overall organic growth was 1.6% acquisitions accounted.

For 13.2% of our growth and foreign exchange was a headwind of 1.2%.

Now I'd like to turn it over to Tom did bile. So Tom can provide a more in depth review of our financial performance for the quarter.

Thanks, Warren Please turn to slide seven which compares our third quarter results on a GAAP basis to a non-GAAP basis.

As the new CFO with it and then I chose to breakdown or adjustments into two categories are better transparency.

One categories reference this special items on the slide.

These are onetime unusual expenses the other cata golar, Gary called integration non ops includes transition and integration expenses. The company has historically captured due to the number of acquisitions made over the past few years.

The second category of adjustments also includes foreign exchange effects on intercompany loan and some amortization items.

The next slide will provide more detail of our adjustments.

Still on slide seven reading from left to right for both the third quarter 2019.

2018, the first column shows GAAP reported numbers and calculations derived using GAAP numbers.

Second column shows the first category of adjustments special items, which you will recall are generally nonrecurring adjustments.

Third column is non GAPP, excluding special items. The fourth column shows the second category of adjustment integration non.

The fifth column is the total adjusted non-GAAP , which considers both categories of adjust.

Stepping back.

Great year numbers highlighted on the Rightsizing. The page you can see both green and Red shady, indicating both positive and negative variances.

Gross profit on a GAAP basis increased 90 basis points.

non-GAAP gross profit excluding special items increased 60 basis points and total adjusted non op.

non-GAAP gross profit increased 70 basis points.

Operating income on a GAAP basis increased 70 basis point non-GAAP operating income excluding special items increased 90 basis points and total adjusted non-GAAP operating income increased 10 basis points.

EBITDA on a reported basis was up 110 basis points non-GAAP EBITDA, excluding special items increased 120 basis points and total adjusted non-GAAP EBITDA increased 60 basis points.

Bottom line is that we improved gross profit operating income and EBITDA as a percent of sales no matter how you measure.

Transition and integration costs will no longer be reported after the fourth quarter of 2019.

These expenses were shown in the past.

The business transition from a ball Enroller company to a diversified industrial company with three segments life Sciences power solutions and mobile solution.

Let's go to slide eight which provides a bridge with more granularity between reported GAAP non-GAAP , excluding special items and total adjusted non-GAAP .

Tax affected special items in the quarter, where CEO transition costs of point, Sevenmillion and asset impairment charge of point Threemillion related from a relocation from the Johnson City office.

Compared to the prior year, we incurred tax effected special items the point Threemillion, specifically related to that August 2018, Technical Arts acquisition point 4 million of other acquisition transaction costs 5 million of a write off of unamortized debt issuance club point 2 million.

For the reduction of prior restructuring costs and the discrete tax item of $600.

In Q3, 2019 tax affected non operational adjustments were 1.5 million for capacity and capabilities development.

Professional fees, the point 4 million integration and transformation of 4 million foreign exchange on intercompany loans of point, Threemillion, and 9.9 million of amortization of intangibles and deferred financing costs.

Tax affected adjustments in the prior year were 1.8 million for acid and capabilities development professional fees of 1.2 million integration and transformation of 3.4 million foreign exchange on intercompany loans of point 5 million and 9.4 million of amortization of intangible and deferred financing.

Cost.

Again, the bottom line on the right side of the chart shows that our metrics are improving year over year.

Turning to slide nine net working capital at the end of the fiscal third quarter was 202.9 million compared with 207.8 million at the end of the third quarter in the prior year, a decrease of 4.9 million.

Working capital turns were 4.2 versus 4.0 in the prior year.

Our life Sciences segment showed improvements and DSL and inventory turns positively impacting the overall companies result.

Please turn to slide 10.

Net debt at the end of the third quarter was 855 million versus 864 million in the prior year, a decrease of 9 million.

The ratio of EBITDA to funded debt as measured by the credit agreement was 5.1 time versus 4.96 in the prior year.

The company is focused on paying down debt and improving cash flow in the coming quarters.

Slide 11 shows our free cash flow for the quarter and year to date, we generated free cash flow of 17.5 million in the third quarter 2019, compared to a negative free cash flow of 11.9 million in the third quarter of 2018.

The increase in cash flow was partially a result of improvements in working capital management improved operating results and lower capital spending.

Free cash flow was negative 7.1 million on a year to date basis in 2019 and negative 60.2 million in the prior year, primarily due to less cash provided from operations and higher capital expenditure.

It is very important to note that the fourth quarter of 2018 net cash provided by operations and free cash flow at a positive 34.4 million tax refund that will not repeat in the fourth quarter of 2019 as footnoted on that slide.

We anticipate positive cash flow in the fourth quarter and will speak more to this point later in the presentation.

Slide 12 summarizes our capital spending depreciation and amortization trends.

Cash capital expenditures for approximately 11.7 million compared to 18.1 million in the third quarter 2018.

For the quarter companies capital spending was 5.5% of sales down from the prior years percentage of 8.8.

There were there was lower capital spending in Q3 2019 across all our business units compared to the prior year.

On a year to date basis, the company spent 40.7 million or 6.3% of sales versus 47 million or 8.2% of sales in the prior year.

And then anticipate spending a total of 50 million on capital in 2019.

And then has increased its manufacturing capacity and as capital spending has exceeded depreciation expense over the past four years going forward and then we'll focus on directing sales and operating activities to better utilize this capacity and targets capital spending to be in the range of.

4% this will allow us to free up.

Cash to pay down debt with that I'll turn the call back to warrant.

Thanks, Tom we have presented additional information for each of our operating groups starting with the life Sciences group on page 14.

The 20% year over year sales increase has been driven primarily primarily by our orthopedic and delivery system or cased and trade products, yielding an improvement in margins over the prior year.

After the operating profit has increased to 21.8% from 20.7% for the prior year.

As a reminder, approximately 70% to 75% of the adjustments from the GAAP results are due to intangibles amortization. We have also seen expansion of our reported and adjusted EBITDA margins are positive margin trend is the result of continuous process improvement installation of automation and improved perform.

One of our international operations, our backlog is a 186 million a 20 million dollar reduction from Q2, we have recently launched our new steals and the ops planning application that allows us to proactively interact with our customers and improve the process of matching product requirements with expected delivery dates.

As this application is more fully implemented we expect that it will result in a reduction of our backlog.

As we look forward, we expect Q4 to continue the positive trend as it relates to year over year comparisons with a greater than 10% growth expectation in upcoming quarter.

2020 growth expectation is tempered somewhat at 5% to 9% as we do not expect the same level of new product introductions that occurred in 2019.

As we expect and we expect continued margin improvement due to leveraging incremental sales, while continuing to prove our manufacturing processes. During the latter stages of the Paragon integration plan.

The mobile solutions business summary is included on page 15, mobile sales are down 10.7% from a year ago due primarily primarily to sales declines in North America due to programs moving to enter production delays in new business launches a tariff environment that has created uncertainty in the supply chain.

And the impact of the GM strike, which started in mid September .

In spite of the sales reductions both reported EBITDA and adjusted EBITDA increased as a percentage of sales over Q3 2018, the impact of the sales reduction has been offset by reduction in fixed costs.

Through the end of September 2019, indirect labor SGN, a labor and related benefits were reduced by $4.9 million on an annualized basis. The results of the quarter were also positively impacted by the settlement of litigation with a customer that had defaulted on a supply contract.

As previously announced the mobiles fourth quarter results will be adversely impacted by the United Auto workers strike that concluded on October 25th.

Based on our current customer inventories schedules, we do not believe that the loss volume will be recovered during the fourth quarter. It will likely occur after the first of the year.

We expect modest growth for this group in 2020 due to start a production on some new programs and the focus will be on margin improvement through manufacturing process improvements and additional reduction of fixed costs, including the carryover impact of some of the completed 2019 indirect labor reductions.

In addition, improved free cash flow is expected from reduced capital expenditures and improvement in working capital management, including reduced inventory levels.

Moving to power solutions as previously discussed power sales increased 2.9% year over year was driven by organic growth.

Due to increased demand from smart meters and incremental sales associated with the technical Arts acquisition GAAP operating profit and adjusted operating profit both increased in comparison to prior years by 120 basis points and 90 basis points, respectively margin improvement is due to reduction in indirect NSG any labor.

And direct labor efficiencies.

We expect moderate sales growth during 2020 coming from both electrical and aerospace and defense with continued margin expansion due to optimization of our facility footprint such as the closure of our Fairfield facility and continuous process improvement power will continue to generate significant free cash flow due to high.

Higher EBITDA margins in a low capital expenditure profile.

Lastly, we've summarized our guidance for the fourth quarter in the year on page 18.

As it relates to sales and EBITDA guidance is the same as previously announced on October 29.

Sales for the fourth quarter are expected to be in the range of 190 million to 203 million within adjusted EBITDA range from 31 to 36 million.

We expect positive free cash flow of 12 to 22 million with an adjusted EPS of 12 to 18 cents.

Please note. These estimates assume the current debt structure remains in place through the end of this year.

That concludes our prepared remarks, and we will now turn the call back to the operator for questions.

You would like to ask a question. Please signal by pressing star one on your telephone keypad using speakerphone. Please be sure that your mute function of turned off.

Thanks.

Again that star one you ask a question.

So just a moment to allow everyone the opportunity to signal for questions.

Our first question will be from Rob Brown with Lake Street capital markets.

Good morning.

Turning first to the life.

Scientists business I think you talked about growth rates in 2020 in the high single digits.

Just a little more color there and is that a slowing from your prior.

Thinking or is that is that sort of in line with your expectation.

I think that's that's in line with our expectation one of the things that we've been expecting.

Due to the significant number of new product.

[noise] excuse me new product introductions in that business.

Was that that would that pace of the new product introductions would slow down starting in the first quarter or the first half of next year and we're seeing that in our business. So the growth. This single digit growth rates from 5% to 9% is inline with our expectations.

Okay. Good.

And then.

In the mobile business I guess just wanted to clarify your thinking there how do you see that at this point with this market cycle.

Is it is it down again in 2020, and I think some new programs, maybe offset some of that but help me understand I guess why that business should.

Should not decline in 2020 again.

Yeah, we don't expect a decline in 2020, primarily due to some new program launches that frankly, we anticipated in 2019 that were delayed we.

We've also had we've seen a delay in some of the volumes due to the tariff environment and we've been working with our customers customers to make sure that some of the capacity that we have in place today is more fully utilized in 2020.

Okay. Okay, Great and then last question I guess on the on the financing discussion you talked about.

So you're sort of resetting your thinking on what are sort of the alternative you're looking at and.

What's the timeline, you're you're hoping for.

Yeah, I think the most important thing for US there is that we put a capital structure in place that is aligned with our strategic plan. So we're going to be very thoughtful and the way that we go about this we haven't set a specific timeline, we understand the urgency surrounding it so we're approaching net with that in May.

Mind.

But we are continuing to talk to our lenders and going through various structures and trying to optimize the structure that would make the most sense for us vis-a-vis our strategic plan.

Okay. Thank you okay.

Our next question will be from Steve Barger.

The bank capital markets.

Hey, good morning, guys.

All right warning.

Really nice improvement on the slide deck, thanks for that.

My first question is how long have JP Morgan and the law firm been engaged I'm, just trying to get a sense of where we are in the strategic review.

Yes, both of those JP, Morgan and since since and batch or our trusted advisors to the company and have been for an extended period of time more recently, we've we've focus some of their efforts to helping us evaluate our strategic options so well.

Go forward with that with them and are excited about the prospect.

Did that process started a couple of months ago or a couple of weeks ago.

It's it's it's more recent than a couple of weeks ago excuse me more.

Extended then just a couple of weeks ago. The board goes through annually, a planning process, where we evaluate evaluate the strategic direction of the company's so for US. It's an ongoing process with the recent changes that we've seen in the business as it relates to the goals of de leveraging and.

We have had to redefine how we look at the strategic plan and we're in the process of doing that but it's an ongoing process.

It's really good to see the 32 million in cash savings skewed towards debt reduction can you give any early look at how you think about 2020 free cash flow and realistically is there a path to significant debt pay down without asset sales.

Yes, there is it's through better working capital management, obviously with the elimination of the dividend.

Looking at certain.

Let's say plant optimization movements, along with these SGN a reduction so we have a line of sight that we're going to be reducing debt in 2020.

I think Steve what you've seen two in the third quarter with the 17 and a half 17, and a half million dollar reduction and our expectation for the fourth quarter. You know this this management team and this board is extremely focused on deleveraging the business and this is in our view just the beginning of that.

Yeah. No question you good good job on free cash flow in Threeq you unexpected for Q is it reasonable to think going forward that you could be free cash flow positive and all the quarters are you still going to be a draw in the first half and then.

Ah Ah source in the back half.

I don't want to promise anything at this time, but I mean.

Ultimate goal eventually would be positive free cash flow every quarter.

The seasonality of the business too I would add Steve the seasonality of the business. The first quarter is one where we come out you know and there is some inventory build in some receivable build and we're analyzing some of that right now, but that probably from a seasonality standpoint is the most difficult quarter from a free cash flow standpoint.

Right and last one for me the press release of the strategic options include a sale or part or all of NN.

I'm sure. It's not lost on you the public and private companies that look like life Sciences trade, a double digit EBITDA margins. So if you're going to sell something wouldn't it be better to divest mobile and or power. So shareholders can really get the benefit of a de levered balance sheet and what is really clearly a great business in life Sciences.

Yeah, we're not going to speak specifically about.

How we're going to approach that are what businesses are most likely if any to be sold were going to go through the process with the goal in mind of doing what's best for our shareholders I'm trying to maximize value and also trying to create a scenario where we have the most certain approach as it relates to de leveraging the.

Company, that's our goal.

Understood. Thank you.

Thank you and once again that is star one on your telephone keypad to ask an audio question. Our next question will be from Daniel Moore CJS Securities.

Good morning, Tom Good morning, and Echo thanks for the the additional transparency.

Relates to the presentation very helpful.

Wanted to start with maybe just start Tom with the balance sheet and you talked about cost profile of potential refinancing of the credit facility where are we today, maybe just walk us have you updated terms.

So the tranches of debt what your expectations look like for interest expense for for Q4 and.

Any color on timing of you know I'm sort of the goal of when you might.

Be in position to improve the overall interest expense profile.

Well as I said, you know for our Q4, what we've modeled into the guidance that that war and went over is that you know there's going to be no new refinancing before the end of the year that's over.

I have in our guidance I'm going forward you know obviously with the markets. We will have higher interest expense, we have that one tranche coming up in a year from April that that will become current though our term b and so we're just looking at various different structures to try to.

Try to do the best thing for what our long range plan is so.

We're looking at all options at this time.

Got it and then very helpful color in terms of the outlook for 2020 across the segments any commentary at this point I'm as it relates to margin profile or potential improvement given some of those costs restructuring initiatives.

While we expect to improve margins as we move forward you know as volume increases and plus with our cost reduction and plant optimization.

DNA reductions you know margin should improve going forward, but.

We're not guiding on that until the fourth quarter, which will give them. When we issue. Our 10-K and have this next conference call, which will be it right in March.

Understood. Thank you I'll jump back with any follow ups.

All right Dan Thanks.

Thank you and once again, that's star one to ask an audio question now.

Our next question will be from Steve Barger with Keybanc capital markets.

Yeah.

Primary working cap got down to $203 million in the quarter.

Or can that go or just how much more cash can you take out of working cap and then where can you get on the cash conversion cycle days as you think about going into next year.

This is just early days for me Steve.

I I focused on working capital and I mean, you know we're looking at you know all past due receivables you know improving inventory is warrant talked about is lowering inventory. So that we have higher turns more cash coming in and then looking at just DPL terms trying to push those out further so I.

Just in the.

Ben drinking from the fire hose.

I will be focusing on this going forward, if you understand totally get it and just a modeling question. If you. If you have this how should we think about SGN $8.

The spend in dollars next year, and what will run rate corporate expense being.

We're still working through that will give further guidance and in March of next year when we.

Release, our Q4.

And just one more can we just talk about the Capex philosophy for auto and Warren correct me, if I'm wrong, but I think there can be big differences between launching a product you've done in the past even if it's in a new location versus something brand, new where you're building the tooling and kind of writing that learning curve. So how are you approaching the market right now in terms of what pro.

Grams, you're willing to look at.

Yeah. That's it that's a good question Steve So when we look at we look at capital across the organization. We're looking at it from a return on invested capital modeling standpoint, and clearly the mobile group is the most capital intensive of our three businesses and one of the things that we've been working with the team there.

There is trying to redeploy or to deploy a from a sales strategy standpoint existing capacity and that's why we're reasonably confident that we're going to be able to reduce the capex spend there in 2020.

As an example, if you look at the China operation, we probably have the capacity there to manufacture.

You know 60 million of product on an annual basis, which is you know 40% above the current level.

From a sales volume standpoint, so the team is focused on selling into existing capacity today as opposed to pursuing programs that will require significant capex spend.

Understood.

And just going back to life Sciences for a second can you talk about recent conversations or new contract wins, just give us an update on how the model on the value proposition is evolving in the marketplace.

Yeah, you know, we obviously we've had significant success there when you look at the year over year comparison, and we expect that to continue I'm going now one of the things that the team. There has done is weve modernized some of the facilities through additional investments and machining.

Capability and just as important on the automation side Theres been a lot of automation put in to make us more cost effective from a labor standpoint that will that that is ongoing and I would tell you. Some of that action really is what makes us an indispensable supplier to some of our.

When customers so the ongoing quoting in the hit rate continues to be extremely positive and we expect that business to be a solid performer for us obviously going forward.

That's great color, Thanks, and maybe I missed this I.

In the prior life Sciences question, but what would have to happen for you to hit the lower end of that 5% to 9% because given the backlog you've seen in the value proposition in life Sciences. It seems like that would require a pretty significant end market slowdown or something.

Yeah, I think I I think we're going to stick with the 5% to 9% range. It's hard to speculate you know what what specific events could happen that would drive us to the lower end of the range. That's what we're looking at right now and it's certainly new product introductions can impact that either positively or negatively.

Which require an inventory Phil, but we'll learn more about that in the upcoming months.

Got it thanks.

Thank you. Our next question will be from Daniel Moore with CJS Securities.

Thanks again, just a quick clarification on the go forward guidance you will it sounds like in 2020 no longer be.

Backing out John transition related types expenses is that is that indicate a likelihood that those will be fairly minimal from your perspective right now in 2020 or that could there be you know some oh, let's say delta between you know where where we.

It's kind of finished the year this year and what 2020 could look like from an adjusted EBITDA perspective, just trying to get a sense of those your thoughts on add backs for next year.

Well my thoughts on add backs as I don't like add backs up and those are going down substantially next year as as you know that there's so many portfolio moves in this business. So.

It goes down to a minimal results as the business is actually absorbing we will definitely do reconciliations to the prior year to show what it is we'll comment in the M. DNA on on certain things that are let's say suppressing margins should we have new product launches such as we had this year two large ones one and.

Mobile one in life Sciences, you know will be very very transparent and you'll be able to reconcile.

All right very helpful. I think it will be well receive thanks.

[laughter].

Yeah.

Thank you I'm showing no further questions in queue at this time.

This concludes today's teleconference. You may now disconnect. Thank you.